Birchview Capital LP Sells 2,500 Shares of United Therapeutics Corporation $UTHR

Key Points

• Birchview Capital LP has sold 2,500 shares of United Therapeutics Corporation, reducing its stake by 25%, leaving it with 7,500 shares valued at approximately $2.3 million.
• United Therapeutics has faced a 0.8% drop in stock value recently, currently trading around $304.76 with a market cap of $13.75 billion and a PE ratio of 11.90.
• The company reported earnings of $6.41 per share, which was below analyst expectations, but still showed a year-over-year revenue increase of 11.7%.

Birchview Capital LP trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 25.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 7,500 shares of the biotechnology company's stock after selling 2,500 shares during the period. United Therapeutics comprises 2.0% of Birchview Capital LP's investment portfolio, making the stock its 13th biggest position. Birchview Capital LP's holdings in United Therapeutics were worth $2,312,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. SVB Wealth LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth approximately $32,000. Dunhill Financial LLC increased its position in shares of United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the last quarter. Sound Income Strategies LLC bought a new stake in United Therapeutics during the first quarter worth $49,000. Brooklyn Investment Group boosted its position in United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC purchased a new position in United Therapeutics in the first quarter worth $60,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 0.8%

NASDAQ UTHR opened at $304.76 on Tuesday. The company has a market cap of $13.75 billion, a PE ratio of 11.90, a price-to-earnings-growth ratio of 4.62 and a beta of 0.62. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The firm's 50-day simple moving average is $299.03 and its two-hundred day simple moving average is $304.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.85 EPS. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on UTHR shares. UBS Group raised their target price on United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a "buy" rating in a research report on Thursday, July 31st. Morgan Stanley decreased their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Wells Fargo & Company dropped their target price on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $382.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer owned 8,118 shares in the company, valued at $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at $10,297,208.76. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock valued at $24,537,839 over the last 90 days. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.